2023-03-16 14:42:30 ET
- Paratek Pharmaceuticals press release ( NASDAQ: PRTK ): Q4 GAAP EPS of -$0.13 misses by $0.23 .
- Revenue of $75.6M (+137.7% Y/Y) beats by $12.13M .
- Shares -26% .
-
Paratek also announced its full-year 2023 revenue guidance, which is expected to be in the range of $143.0 to $158.0 million, which includes the following components:
- NUZYRA net U.S. sales of approximately $125.0 to $135.0 million.
- BARDA government contract service and grant revenue between $15.0 to $20.0 million.
- Royalty and collaboration revenue of approximately $3.0 million.
Paratek expects to reduce full-year 2023 R&D and SG&A expense below that incurred in 2022.
For further details see:
Paratek Pharmaceuticals GAAP EPS of -$0.13 misses by $0.23, revenue of $75.6M beats by $12.13M